- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
1 report, 1 independent
Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Veradermics, Incorporated is seeking federal regulatory approval from the FDA for its drug candidates.
- Oversight failures and regulatory inertia in the U.S. drug approval process were exposed on August 3rd, involving the FDA and Merck.
The entities involved
Related events
- Cronus Pharma LLC, headquartered in East Brunswick, is launching products in the U.S. market and seeking FDA approval.
- FDA approves products sold in Wisconsin stores, with business operations centered in Northeast Wisconsin.
- A product was launched in the U.S. market following FDA involvement.
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.